Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Konstantin Tachkov, Vladimira Boyadzhieva, Ivan Manev, Nikolay Stoilov, Zornitsa Mitkova, Konstantin Mitov & Guenka Petrova. (2022) Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level. Biotechnology & Biotechnological Equipment 36:1, pages 828-837.
Read now
Read now
Brian C. Sauer, Chia-Chen Teng, Tao He, Jianwei Leng, Chao-Chin Lu, Jessica A. Walsh, Neel Shah, David J. Harrison, Derek H. Tang & Grant W. Cannon. (2016) Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. Journal of Medical Economics 19:1, pages 34-43.
Read now
Read now
Vasilis Fragoulakis, Elli Vitsou, Ana Cristina Hernandez & Nikolaos Maniadakis. (2015) Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece. ClinicoEconomics and Outcomes Research 7, pages 85-93.
Read now
Read now
Machaon Bonafede, Barbara H. Johnson, Nicole Princic, Neel Shah & David J. Harrison. (2015) Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics 18:5, pages 376-389.
Read now
Read now
Joaquín Borrás-Blasco & Andres Navarro Ruiz. (2015) Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 71-79.
Read now
Read now
Machaon Bonafede, George J Joseph, Neel Shah, Nicole Princic & David J Harrison. (2014) Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population. ClinicoEconomics and Outcomes Research 6, pages 381-388.
Read now
Read now
Articles from other publishers (13)
Léa Frantzen, Jean-David Cohen, Sonia Tropé, Morgane Beck, Audrey Munos, Mariannick Sittler, Rita Diebolt, Isabelle Metzler, Laurent Arnaud, Jacques-Éric Gottenberg & Christelle Sordet. (2019) Information et perception des patients au sujet des biosimilaires en rhumatologie. Revue du Rhumatisme 86:6, pages 591-596.
Crossref
Crossref
Léa Frantzen, Jean-David Cohen, Sonia Tropé, Morgane Beck, Audrey Munos, Marie-Annick Sittler, Rita Diebolt, Isabelle Metzler & Christelle Sordet. (2019) Patients’ information and perspectives on biosimilars in rheumatology: A French nation-wide survey. Joint Bone Spine 86:4, pages 491-496.
Crossref
Crossref
Jennifer Nergard-Martin, Fariha Siddiqui, Ajay Kailas, Monet Winslow & James A Solomon. (2017) Why Outcome Measures in Dermatology Are Becoming Patient Centric. Current Dermatology Reports 6:3, pages 178-185.
Crossref
Crossref
Sergio Schwartzman, Yunfeng Li, Huanxue Zhou & Jacqueline B. Palmer. (2017) Economic impact of biologic utilization patterns in patients with psoriatic arthritis. Clinical Rheumatology 36:7, pages 1579-1588.
Crossref
Crossref
Jacqueline B. Palmer, Yunfeng Li, Vivian Herrera, Minlei Liao, Melody Tran & Zafer E. Ozturk. (2016) Treatment patterns and costs for anti-TNF? biologic therapy in patients with psoriatic arthritis. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang & Debra F. Eisenberg. (2016) Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes 3:4, pages 369-381.
Crossref
Crossref
Joannes A. A. Reijers, T. van Donge, F. M. L. Schepers, J. Burggraaf & J. Stevens. (2016) Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. European Journal of Clinical Pharmacology 72:11, pages 1343-1352.
Crossref
Crossref
Grant W. Cannon, Scott L. DuVall, Candace L. Haroldsen, Liron Caplan, Jeffrey R. Curtis, Kaleb Michaud, Ted R. Mikuls, Andreas Reimold, David H. Collier, George J. Joseph, David J. Harrison & Brian C. Sauer. (2016) Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Advances in Therapy 33:8, pages 1347-1359.
Crossref
Crossref
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Martina Biggioggero, Maurizio Benucci, Francesca Li Gobbi, Valentina Grossi, Maria Infantino, Francesca Meacci, Mariangela Manfredi, Serena Guiducci, Silvia Bellando-Randone, Marco Matucci-Cerinic, Rosario Foti, Marcella Di Gangi, Marta Mosca, Chiara Tani, Fabrizio Palmieri & Delia Goletti. (2016) Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 45:5, pages 519-532.
Crossref
Crossref
Benjamin Chastek, John White, Damon Van Voorhis, Derek Tang & Bradley S. Stolshek. (2016) A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients. Advances in Therapy 33:4, pages 626-642.
Crossref
Crossref
Emily J. Mckeown. (2015) The ethical challenges in rheumatology. Current Reviews in Musculoskeletal Medicine 8:2, pages 107-112.
Crossref
Crossref
Stephen S. Johnston, Donna McMorrow, Amanda M. Farr, Paul Juneau & Sarika Ogale. (2015) Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic. Drugs - Real World Outcomes 2:1, pages 99-109.
Crossref
Crossref
Ning Wu, Yuan-Chi (Daisy) Lee, Neel Shah & David J. Harrison. (2014) Cost of Biologics per Treated Patient across Immune-mediated Inflammatory Disease Indications in a Pharmacy Benefit Management Setting: A Retrospective Cohort Study. Clinical Therapeutics 36:8, pages 1231-1241.e3.
Crossref
Crossref